Drug Profile
LB 100
Alternative Names: LB-1; LB-100Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Lixte Biotechnology Holdings
- Developer City of Hope National Medical Center; Grupo Espanol de Investigacion en Sarcomas; INSERM; Lixte Biotechnology Holdings; M. D. Anderson Cancer Center; National Cancer Institute (USA)
- Class Anti-ischaemics; Antidepressants; Antineoplastics; Behavioural disorder therapies; Carboxylic acids; Heterocyclic bicyclo compounds; Piperazines; Small molecules
- Mechanism of Action Protein phosphatase 2A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Myelodysplastic syndromes; Ovarian cancer; Soft tissue sarcoma
- Phase I Small cell lung cancer
- Preclinical Behavioural disorders
- No development reported Angelman syndrome; Ischaemia; Solid tumours
- Discontinued Depressive disorders; Haematological disorders
Most Recent Events
- 26 Feb 2024 Lixte Biotechnology along with National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI) expand Cooperative Research and Development Agreement (CRADA) for LB 100
- 13 Nov 2023 Phase-I/II clinical trials in Ovarian cancer (Combination therapy; Metastatic disease, Second-line therapy or greater) in USA (IV) before November 2023 (NCT06065462)
- 02 Nov 2023 The Netherlands Cancer Institute plans a phase I trial for Colorectal Cancer (Combination therapy, Metastatic disease) in April 2024 (IV) (NCT06109883)